secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001274737-21-000113
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen Q3 2021 revenue $12.3M (+14% YoY); net loss widens to $7.2M; reaffirms FY guidance
--------------------------------------------------------------------------------

- Total revenue $12.3M, up 14% YoY; AVISE CTD revenue $9.9M (+34% YoY) on 31,742 tests (+21%).
- Net loss of $7.2M vs. $4.3M a year ago; operating expenses rose to $18.8M from $14.6M.
- Record 1,969 ordering HCPs and 714 adopters; sequential quarterly retention ~99%.
- Signed agreement with Inland Empire Health Plan; in-network lives now ~68.9M.
- Entered pilot to supply AVISE MTX to retail pharmacy chain & major payor partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473721000113/0001274737-21-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473721000113/exdx-20211110.htm
  HTML page:      https://secwatch.observer/filing/0001274737-21-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer